|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0013216,
umls-concept:C0020538,
umls-concept:C0030705,
umls-concept:C0148199,
umls-concept:C0205179,
umls-concept:C0684249,
umls-concept:C1274040,
umls-concept:C1513884,
umls-concept:C1521808,
umls-concept:C1698364,
umls-concept:C1999216,
umls-concept:C2603343
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2010-10-25
|
|
pubmed:abstractText |
Hypertension (HTN), a recognized adverse effect of angiogenesis inhibitors, may be a potential biomarker of activity of these agents. We conducted a retrospective analysis to examine the incidence and predictors of the development of on-treatment HTN with the vascular endothelial growth factor receptor tyrosine kinase inhibitor cediranib, and the relationship of this adverse event with treatment outcomes.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1569-8041
|
|
pubmed:author |
pubmed-author:ArnoldAA,
pubmed-author:CiuleanuTT,
pubmed-author:DediuMM,
pubmed-author:DinaMM,
pubmed-author:EllisP MPM,
pubmed-author:FentonDD,
pubmed-author:GoodwinRR,
pubmed-author:LabergeFF,
pubmed-author:LaurieS ASA,
pubmed-author:LeMaîtreAA,
pubmed-author:NCIC Clinical Trials Group, Kingston, Ontario, Canada,
pubmed-author:SeymourLL,
pubmed-author:ShepherdF AFA,
pubmed-author:VincentMM,
pubmed-author:WaldeDD,
pubmed-author:ZukinMM
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
21
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2220-6
|
|
pubmed:meshHeading |
pubmed-meshheading:20427348-Adenocarcinoma,
pubmed-meshheading:20427348-Adult,
pubmed-meshheading:20427348-Aged,
pubmed-meshheading:20427348-Aged, 80 and over,
pubmed-meshheading:20427348-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20427348-Carboplatin,
pubmed-meshheading:20427348-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:20427348-Carcinoma, Squamous Cell,
pubmed-meshheading:20427348-Double-Blind Method,
pubmed-meshheading:20427348-Drug Therapy, Combination,
pubmed-meshheading:20427348-Female,
pubmed-meshheading:20427348-Humans,
pubmed-meshheading:20427348-Hypertension,
pubmed-meshheading:20427348-Lung Neoplasms,
pubmed-meshheading:20427348-Male,
pubmed-meshheading:20427348-Middle Aged,
pubmed-meshheading:20427348-Neoplasm Staging,
pubmed-meshheading:20427348-Paclitaxel,
pubmed-meshheading:20427348-Placebos,
pubmed-meshheading:20427348-Quinazolines,
pubmed-meshheading:20427348-Receptors, Vascular Endothelial Growth Factor,
pubmed-meshheading:20427348-Retrospective Studies,
pubmed-meshheading:20427348-Survival Rate,
pubmed-meshheading:20427348-Treatment Outcome
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24.
|
|
pubmed:affiliation |
NCIC Clinical Trials Group, Queen's University, Kingston, Ontario, Canada.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
